Do immunosuppressive treatments influence immune responses against adenovirus-based COVID-19 vaccines in patients with multiple sclerosis? An Argentine multicenter study
Open Access
- 19 August 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1431403
Abstract
Introduction: There are no reports in LATAM related to longitudinal humoral and cellular response to adenovirus based COVID-19 vaccines in people with Multiple Sclerosis (pwMS) under different disease modifying therapies (DMTs) and neutralization of the Omicron and Wuhan variants of SARS-COV-2.Methods: IgG anti- SARS-COV-2 spike titer were measured in a cohort of 101 pwMS under fingolimod, dimethyl fumarate, cladribine and antiCD20, as well as 28 healthy controls (HC) were measured 6 weeks after vaccination with 2nd dose (Sputnik V or AZD1222) and 3nd dose (homologous or heterologous schedule). Neutralizing capacity was against Omicron (BA.1) and Wuhan (D614G) variants and pseudotyped particles and Cellular response were analyzed.Results: Multivariate regression analysis showed anti-cd20 (β= -,349, 95% CI: -3655.6 - -369.01, p=0.017) and fingolimod (β=-,399, 95% CI: -3363.8 - -250.9, p=0.023) treatments as an independent factor associated with low antibody response (r2 adjusted=0.157). After the 2nd dose we found a correlation between total and neutralizing titers against D614G (rho=0.6; p<0.001; slope 0.8, 95%CI:0.4-1.3), with no differences between DMTs. Neutralization capacity was lower for BA.1 (slope 0.3, 95%CI:0.1-0.4). After the 3rd dose, neutralization of BA.1 improved (slope: 0.9 95%CI:0.6-1.2), without differences between DMTs. A fraction of pwMS generated anti-Spike CD4+ and CD8+ T cell response. In contrast, pwMS under antiCD20 generated CD8+TNF+IL2+ response without differences with HC, even in the absence of humoral response. The 3rd dose significantly increased the neutralization against the Omicron, as observed in the immunocompetent population.Discussion: Findings regarding humoral and cellular response are consistent with previous reports.Keywords
This publication has 48 references indexed in Scilit:
- Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimodJournal of Neurology, 2022
- Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With OcrelizumabJAMA Neurology, 2022
- Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 VaccinationJAMA Neurology, 2022
- Omicron’s message on vaccines: Boosting begets breadthCell, 2022
- COVID‐19 Vaccine Response in People with Multiple SclerosisAnnals of Neurology, 2021
- Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With OcrelizumabJAMA Neurology, 2021
- Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple SclerosisJAMA Neurology, 2020
- Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity OutcomesJAMA, 2020
- Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosisJournal of Neurology, 2020
- Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral ImmunityJAMA Neurology, 2016